C. R. M. Asquith

The paper identifies and optimizes narrow-spectrum TLK2 inhibitors using QSAR analysis and structural studies.

The paper develops small molecule inhibitors and activators for COQ8A, a UbiB family protein, using crystallography, NMR, and mass spectrometry to modulate its function in CoQ biosynthesis.

This study shows that Numb-associated kinases are essential for SARS-CoV-2 infection and that inhibiting them can suppress viral infection in human lung cells.

This paper designs and tests 4-anilinoquinoline inhibitors targeting cyclin G-associated kinase (GAK) by analyzing water networks in the ATP binding site.

The paper identifies 7-iodo-N-(3,4,5-trimethoxyphenyl)quinolin-4-amine as a potent PKN3 inhibitor with an IC50 of 1.3 μM in cells, suggesting its potential as a tool for studying PKN3 biology and therapeutic applications.

The paper introduces the Kinase Chemogenomic Set (KCGS), a curated collection of 187 selective kinase inhibitors covering 215 human kinases, for use in cell-based screens.

The paper designs and synthesizes 4-anilino-quin(az)oline compounds to analyze their kinase inhibition profiles and structure-activity relationships for GAK/SLK/STK10 targets.

The paper identifies novel anti-tubercular compounds from 4-anilinoquinolines and 4-anilinoquinazolines with high potency and low toxicity.

The paper develops SGC-GAK-1 as an orally active in vivo probe for GAK by using cytochrome P450 inhibition to improve its metabolic stability and plasma exposure.

The paper designs and evaluates novel 4-anilinoquinolines and quinazolines as EGFR inhibitors, identifying a potent compound for lung cancer and chordoma treatment.

The paper describes SGC-GAK-1, a selective GAK inhibitor, and identifies a related compound that inhibits RIPK2 without GAK activity, providing tools to study GAK and RIPK2 biology.

The paper identifies 4-anilinoquinolines as potent GAK inhibitors with high selectivity and suggests their potential as tools for studying GAK's role in infectious diseases.